Stock Events

Stock Events

Redhill Biopharma 

$0.6562
78
+$0.00+0.44% 16:54 Today

Statistics

Day High
0.6799
Day Low
0.6501
52W High
2.79
52W Low
0.57
Volume
109,505
Avg. Volume
1,867,412
Mkt Cap
3.99M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

10JunExpected
Q3 2021
Q4 2021
Q1 2022
Q3 2022
Q1 2023
Q3 2023
Q1 2024
-0.5
-0.33
-0.17
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-150%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
286,000Revenue
-429,000Net Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RDHL. It's not an investment recommendation.
Apple
13
AAPL
Microsoft
10
MSFT
NVIDIA
8
NVDA
Tesla
7
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap453.19B
AbbVie competes in the gastrointestinal and infectious disease markets, similar to Redhill's focus areas.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences has a strong presence in the development of antiviral drugs, directly competing with Redhill's infectious disease portfolio.
Merck
MRK
Mkt Cap370.89B
Merck is involved in creating therapies for infectious diseases, including treatments that could overlap with Redhill's product offerings.
Pfizer
PFE
Mkt Cap162.16B
Pfizer has a broad range of products that compete in the infectious disease space, making it a competitor to Redhill.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca operates in various therapeutic areas, including infections and gastrointestinal diseases, overlapping with Redhill's interests.
Bristol-Myers Squibb
BMY
Mkt Cap136.49B
Bristol Myers Squibb develops drugs in areas that compete with Redhill's focus, including gastrointestinal diseases.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the infectious disease market.
Sanofi
SNY
Mkt Cap106.01B
Sanofi has a diversified portfolio that includes treatments for infectious diseases, competing with Redhill.
Novartis
NVS
Mkt Cap304.1B
Novartis offers medications in several areas, including those that compete with Redhill's therapeutic focus.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.22B
Regeneron Pharmaceuticals focuses on innovative treatments, including for infectious diseases, making it a competitor to Redhill.

About

RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
Show more...
CEO
Dror Ben-Asher
Employees
23
Country
Israel
ISIN
US7574683014
WKN
000A40MF2

Listings

STU
DE
2RH.STU
MU
DE
2RH.MU
BOATS
BOATS
RDHL.BOATS
F
DE
2RH.F

0 Comments

Share your thoughts

FAQ

What is Redhill Biopharma stock price today?▼
The current price of RDHL is $0.66 USD — it has increased by +0.44% in the past 24 hours. Watch Redhill Biopharma stock price performance more closely on the chart.
What is Redhill Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Redhill Biopharma stocks are traded under the ticker RDHL.
Is Redhill Biopharma stock price growing?▼
RDHL stock has fallen by -8.74% compared to the previous week, the month change is a +3.52% rise, over the last year Redhill Biopharma has showed a -58.68% decrease.
What is Redhill Biopharma market cap?▼
Today Redhill Biopharma has the market capitalization of 3.99M
What is Redhill Biopharma revenue for the last year?▼
Redhill Biopharma revenue for the last year amounts to 286,000 USD.
What is Redhill Biopharma net income for the last year?▼
RDHL net income for the last year is -429,000 USD.
How many employees does Redhill Biopharma have?▼
As of September 11, 2026, the company has 23 employees.
In which sector is Redhill Biopharma located?▼
Redhill Biopharma operates in the Health & Wellness sector.
When did Redhill Biopharma complete a stock split?▼
The last stock split for Redhill Biopharma was on August 20, 2024 with a ratio of 1:25.
Where is Redhill Biopharma headquartered?▼
Redhill Biopharma is headquartered in Tel Aviv, Israel.